Thursday, October 30, 2014
Resveratrol, the antioxidant compound found primarily in red wine, grapes and nuts, is well known for its anti-aging and possible anti-cancer effects. In a recent study, Danish researchers have identified yet another role for this popular antioxidant. They found that a high dose of resveratrol increased spinal bone density among men with metabolic syndrome and could hold promise.
Danish researchers set out to investigate whether resveratrol could be useful in men with metabolic syndrome. Metabolic syndrome is a condition characterised by low-grade inflammation that can cause bone loss. The anti-inflammatory properties of resveratrol may protect against bone loss according to their study published in the Journal of Clinical Endocrinology & Metabolism.
The researchers conducted a randomised, double-blinded, placebo-controlled trial that assessed bone mineral density and signs of bone formation and resorption in 66 middle-aged men with metabolic syndrome. The men were either given a 500-miligram dose of resveratrol, a 75-miligram dose of the compound or a placebo twice a day for 16 weeks.
The men who took the higher dose of resveratrol recorded a 2.6% increase in lumbar spine volumetric bone mineral density compared to the men who had taken placebo. They also had a 16% increase in the levels of the bone formation marker bone alkaline phosphatase (BAP) compared to the control group.
"Our study is the first to reveal resveratrol's potential as an anti-osteoporosis drug in humans," said the lead researcher Marie Juul Ørnstrup. She further adds, “In just four months on high-dose resveratrol, we saw significant improvements in bone mineral density at the spine and elevated levels of the bone formation marker BAP. These are encouraging results.”
Whether reseveratrol confers bone-protective effects on populations at risk of osteoporosis during long-term treatment is still unknown. Further research is needed to unravel the added benefits of the wonder compound resveratrol.
For study details:-Click Here!